Edition:
United Kingdom

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.25USD
19 Jan 2018
Change (% chg)

$0.05 (+2.27%)
Prev Close
$2.20
Open
$2.17
Day's High
$2.25
Day's Low
$2.15
Volume
197,999
Avg. Vol
429,865
52-wk High
$4.09
52-wk Low
$1.59

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €518.56
Shares Outstanding(Mil.): 156.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.28 16.58
EPS (TTM): -- -- --
ROI: -- 13.90 10.60
ROE: -- 16.71 14.19

BRIEF-Antares Pharma Provides Xyosted Regulatory Update

* ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED

16 Jan 2018

BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted

* ANTARES PHARMA - WRITTEN REQUEST FOR A TYPE A MEETING HAS BEEN SUBMITTED TO FDA IN RESPONSE TO CRL RECEIVED REGARDING NDA FOR XYOSTED Source text for Eikon: Further company coverage:

21 Dec 2017

BRIEF-Antares Pharma Q3 loss per share $0.03

* Antares Pharma reports third quarter 2017 operating and financial results

07 Nov 2017

BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted

* Antares pharma receives complete response letter from the fda for Xyosted

20 Oct 2017

BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

* Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​

12 Oct 2017

BRIEF-Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

* Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

10 Oct 2017

BRIEF-Antares Pharma entered sales agreement with cowen and co to offer, sell shares of its common stock, par value $0.01/share- SEC Filing

* Antares Pharma-on Aug 11,entered sales agreement with Cowen and Company under which co may offer, sell shares of its common stock,par value $0.01/share

11 Aug 2017

BRIEF-Antares Pharma Q2 loss per share $0.02

* Antares pharma reports second quarter 2017 operating and financial results

08 Aug 2017

Earnings vs. Estimates

No consensus analysis data available.